Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
1949- PL,    Design, synthesis, and biological evaluation of a novel indoleamine 2,3-dioxigenase 1 (IDO1) and thioredoxin reductase (TrxR) dual inhibitor
- in-vitro, CRC, HCT116 - in-vitro, Cerv, HeLa
TrxR↓, selectivity↑, ROS↑, IDO1↓,
1950- PL,    Increased Expression of FosB through Reactive Oxygen Species Accumulation Functions as Pro-Apoptotic Protein in Piperlongumine Treated MCF7 Breast Cancer Cells
- in-vitro, BC, MCF-7 - in-vitro, Lung, A549
selectivity↑, ROS↑, SETBP1↓, cl‑Casp9↑, eff↓, FOSB↑,
1951- PL,    Piperlongumine Analogs Promote A549 Cell Apoptosis through Enhancing ROS Generation
- in-vitro, Lung, A549
ROS↑, lipid-P↑, MMP↓, TumCCA↑, TrxR↓, eff↑,
1952- PL,  5-FU,    Piperlongumine induces ROS accumulation to reverse resistance of 5-FU in human colorectal cancer via targeting TrxR
- in-vivo, CRC, HCT8
ROS↑, TrxR↓, eff↑, p‑Akt↓,
1953- PL,    Designing piperlongumine-directed anticancer agents by an electrophilicity-based prooxidant strategy: A mechanistic investigation
- in-vitro, Lung, A549 - in-vitro, Nor, WI38
ROS↑, selectivity↑, TrxR↓, TumCCA↑, GSH?, H2O2↑,
1938- PL,    Piperlongumine regulates epigenetic modulation and alleviates psoriasis-like skin inflammation via inhibition of hyperproliferation and inflammation
- Study, PSA, NA - in-vivo, NA, NA
ROS↑, Apoptosis↑, MMP↓, TumCCA↑, DNAdam↑, STAT3↓, Akt↓, PCNA↓, Ki-67↓, cycD1/CCND1↓, Bcl-2↓, K17↓, HDAC↓, ROS↑, *IL1β↓, *IL6↓, *TNF-α↓, *IL17↓, *IL22↓,
1945- PL,  SANG,    The Synergistic Effect of Piperlongumine and Sanguinarine on the Non-Small Lung Cancer
- in-vitro, Lung, A549
toxicity∅, Apoptosis↑, TumMeta↓, ROS↑, TumCCA↑,
1944- PL,    Piperlongumine, a Novel TrxR1 Inhibitor, Induces Apoptosis in Hepatocellular Carcinoma Cells by ROS-Mediated ER Stress
- in-vitro, HCC, HUH7 - in-vitro, HCC, HepG2
ER Stress↑, TrxR1↓, ROS↑, eff↓, Bcl-2↓, proCasp3↓, BAX↓, cl‑Casp3↑, TumCCA↑, p‑PERK↑, ATF4↑, TumCG↓, lipid-P↑, selectivity↑,
1943- PL,    Piperlongumine treatment inactivates peroxiredoxin 4, exacerbates endoplasmic reticulum stress, and preferentially kills high-grade glioma cells
- in-vitro, GBM, NA - in-vivo, NA, NA
selectivity↑, ROS↑, selectivity↑, Prx4↓, *Prx4∅, ER Stress↑, CHOP↑, UPR↑,
1942- PL,    Piperlongumine inhibits antioxidant enzymes, increases ROS levels, induces DNA damage and G2/M cell cycle arrest in breast cell lines
- in-vitro, BC, MCF-7
ROS↑, SOD1↑, Trx1↓, Catalase↓, PrxII↓, ROS↑, GADD45A↑, P21↑, DNAdam↑, TumCCA↑,
1941- PL,    Piperlongumine selectively kills cancer cells and increases cisplatin antitumor activity in head and neck cancer
- in-vitro, HNSCC, NA
selectivity↑, eff↑, ROS↑, toxicity↑, GSH↓, GSSG↑, *GSSG∅, cl‑PARP↑, PUMA↑, GSTP1/GSTπ↓, ChemoSen↑,
1939- PL,    Piperlongumine selectively kills hepatocellular carcinoma cells and preferentially inhibits their invasion via ROS-ER-MAPKs-CHOP
- in-vitro, HCC, HepG2 - in-vitro, HCC, HUH7 - in-vivo, NA, NA
TumCMig↓, TumCI↓, ER Stress↑, selectivity↑, tumCV↓, ROS↑, GSH↓, eff↓, Ca+2↑, MAPK↑, CHOP↑, Dose↝,
2649- PL,    Oxidative Stress Inducers in Cancer Therapy: Preclinical and Clinical Evidence
- Review, Var, NA
AntiCan↑, ROS↑, GSH↓, TrxR↓, Trx↓, Apoptosis↑, TumCCA↑, ER Stress↑, DNAdam↑, ChemoSen↑, BioAv↓,
2966- PL,    A strategy to improve the solubility and bioavailability of the insoluble drug piperlongumine through albumin nanoparticles
- in-vitro, LiverDam, NA
*Half-Life↑, *BioAv↑, eff↑, ROS↑,
2971- PL,    Piperlongumine attenuates IL-1β-induced inflammatory response in chondrocytes
- NA, OS, NA
*NO↓, *PGE2↓, *iNOS↓, *COX2↓, *MMP3↑, *MMP13↓, *Inflam↓,
2970- PL,    Piperlongumine induces apoptosis and autophagy in leukemic cells through targeting the PI3K/Akt/mTOR and p38 signaling pathways
- in-vitro, AML, NA
AntiAg↑, TumCG↓, Apoptosis↑, PI3K↓, Akt↓, mTOR↓, p38↑, Casp3↑,
2969- PL,    Piperlongumine induces autophagy by targeting p38 signaling
- in-vitro, OS, U2OS - in-vitro, Cerv, HeLa
p38↑, ROS↑, GPx1∅, SOD∅, Catalase∅,
2968- PL,  Chit,    Preparation of piperlongumine-loaded chitosan nanoparticles for safe and efficient cancer therapy
- in-vitro, GC, AGS
eff↑, Dose↝, ROS↑, BioAv↑,
2967- PL,    Piperlongumine and its derivatives against cancer: A recent update and future prospective
- Review, Var, NA
BioAv↓, BioAv↑,
2972- PL,    Piperlongumine Is an NLRP3 Inhibitor With Anti-inflammatory Activity
- in-vitro, AML, THP1
NLRP3↓, IL1β↓, LDH↓, cl‑Casp1↓, Inflam↓,
2973- PL,    The Natural Alkaloid Piperlongumine Inhibits Metastatic Activity and Epithelial-to-Mesenchymal Transition of Triple-Negative Mammary Carcinoma Cells
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, 4T1
MMP2↓, MMP9↓, IL6↓, E-cadherin↑, ROS↑, EMT↓, Zeb1↓, Slug↓, TumMeta↓, selectivity↑, MMP2↓, GSH↓,
2995- PL,    Piperlongumine overcomes osimertinib resistance via governing ubiquitination-modulated Sp1 turnover
- in-vitro, Lung, H1975 - in-vitro, Lung, PC9 - in-vivo, NA, NA
Sp1/3/4↓, cMET↓, Apoptosis↑, Cyt‑c↑, p‑ERK↓, p‑Akt↓, TumCG↓,
2996- PL,    Application of longinamide in inhibiting the activation of NLRP3 inflammasome
- NA, AD, NA - NA, Park, NA
*NLRP3↓,
2999- PL,    Piperlongumine alleviates corneal allograft rejection via suppressing angiogenesis and inflammation
- in-vivo, Nor, HUVECs
*Inflam↓, *angioG↓, *Hif1a↓, *VEGF↓, *ICAM-1↓, *VCAM-1↓, *neuroP↑,
3000- PL,    Biological and physical approaches on the role of piplartine (piperlongumine) in cancer
- in-vitro, Nor, HUVECs - in-vitro, Laryn, HEp2
Inflam↓, AntiTum↑, *α-tubulin↓, selectivity↑, HIF2a↓, MCP1↓,
2956- PL,    Piperlongumine rapidly induces the death of human pancreatic cancer cells mainly through the induction of ferroptosis
- in-vitro, PC, NA
ROS↑, Ferroptosis↓, GSH↓, GPx↓, cl‑PARP∅, cl‑Casp3∅, eff↑, eff↑,
2964- PL,    Preformulation Studies on Piperlongumine
- Analysis, Nor, NA
*BioAv↓, *BioAv↑, *other↝, *eff↓,
2940- PL,    Piperlongumine Induces Reactive Oxygen Species (ROS)-dependent Downregulation of Specificity Protein Transcription Factors
- in-vitro, PC, PANC1 - in-vitro, Lung, A549 - in-vitro, Kidney, 786-O - in-vitro, BC, SkBr3
ROS↑, TumCP↓, Apoptosis↑, eff↓, Sp1/3/4↓, cycD1/CCND1↓, survivin↓, cMyc↓, EGFR↓, cMET↓,
2941- PL,    Selective killing of cancer cells by a small molecule targeting the stress response to ROS
- in-vivo, BC, MDA-MB-231 - in-vitro, OS, U2OS - in-vitro, BC, MDA-MB-453
ROS↑, Apoptosis↑, selectivity↑, *ROS∅, GSH↓, GSSG↑, H2O2↑, NO↑, Half-Life?,
2942- PL,    Piperlongumine increases sensitivity of colorectal cancer cells to radiation: Involvement of ROS production via dual inhibition of glutathione and thioredoxin systems
- in-vitro, CRC, CT26 - in-vitro, CRC, DLD1 - in-vivo, CRC, CT26
ROS↑, GSH↓, TrxR↓, RadioS↑, DNAdam↑, TumCCA↑, mitResp↓, GSTs↓, OS↑,
2943- PL,    Piperlongumine Inhibits Thioredoxin Reductase 1 by Targeting Selenocysteine Residues and Sensitizes Cancer Cells to Erastin
- in-vitro, CRC, HCT116 - in-vitro, Lung, A549 - in-vitro, BC, MCF-7
TrxR1?, TumCD↑, ROS↑, GSH↓, eff↑,
2944- PL,    Piperlongumine, a Potent Anticancer Phytotherapeutic, Induces Cell Cycle Arrest and Apoptosis In Vitro and In Vivo through the ROS/Akt Pathway in Human Thyroid Cancer Cells
- in-vitro, Thyroid, IHH4 - in-vitro, Thyroid, 8505C - in-vivo, NA, NA
ROS↑, selectivity↑, tumCV↓, TumCCA↑, Apoptosis↑, ERK↑, Akt↓, mTOR↓, neuroP↑, Bcl-2↓, Casp3↑, PARP↑, JNK↑, *toxicity↓, eff↓, TumW↓,
2945- PL,    Piperlongumine induces ROS mediated cell death and synergizes paclitaxel in human intestinal cancer cells
- in-vitro, CRC, HCT116
ROS↑, SMAD4↑, ChemoSen↑, P53↑, P21↑, BAX↑, Bcl-2↓, survivin↓, TumCMig↓,
2946- PL,    Piperlongumine, a potent anticancer phytotherapeutic: Perspectives on contemporary status and future possibilities as an anticancer agent
- Review, Var, NA
ROS↑, GSH↓, DNAdam↑, ChemoSen↑, RadioS↑, BioEnh↑, selectivity↑, BioAv↓, eff↑, p‑Akt↓, mTOR↓, GSK‐3β↓, β-catenin/ZEB1↓, HK2↓, Glycolysis↓, Cyt‑c↑, Casp9↑, Casp3↑, Casp7↑, cl‑PARP↑, TrxR↓, ER Stress↑, ATF4↝, CHOP↑, Prx4↑, NF-kB↓, cycD1/CCND1↓, CDK4↓, CDK6↓, p‑RB1↓, RAS↓, cMyc↓, TumCCA↑, selectivity↑, STAT3↓, NRF2↑, HO-1↑, PTEN↑, P-gp↓, MDR1↓, MRP1↓, survivin↓, Twist↓, AP-1↓, Sp1/3/4↓, STAT1↓, STAT6↓, SOX4↑, XBP-1↑, P21↑, eff↑, Inflam↓, COX2↓, IL6↓, MMP9↓, TumMeta↓, TumCI↓, ICAM-1↓, CXCR4↓, VEGF↓, angioG↓, Half-Life↝, BioAv↑,
2947- PL,    Piperlongumine: the amazing amide alkaloid from Piper in the treatment of breast cancer
- Review, Var, NA
TumCP↓, Apoptosis↑, TumCCA↑, ROS↑,
2948- PL,    The promising potential of piperlongumine as an emerging therapeutics for cancer
- Review, Var, NA
tumCV↓, TumCP↓, TumCI↓, angioG↓, EMT↓, TumMeta↓, *hepatoP↑, *lipid-P↓, *GSH↑, cardioP↑, CycB/CCNB1↓, cycD1/CCND1↓, CDK2↓, CDK1↓, CDK4↓, CDK6↓, PCNA↓, Akt↓, mTOR↓, Glycolysis↓, NF-kB↓, IKKα↓, JAK1↓, JAK2↓, STAT3↓, ERK↓, cFos↓, Slug↓, E-cadherin↑, TOP2↓, P53↑, P21↑, Bcl-2↓, BAX↑, Casp3↑, Casp7↑, Casp8↑, p‑HER2/EBBR2↓, HO-1↑, NRF2↑, BIM↑, p‑FOXO3↓, Sp1/3/4↓, cMyc↓, EGFR↓, survivin↓, cMET↓, NQO1↑, SOD2↑, TrxR↓, MDM2↓, p‑eIF2α↑, ATF4↑, CHOP↑, MDA↑, Ki-67↓, MMP9↓, Twist↓, SOX2↓, Nanog↓, OCT4↓, N-cadherin↓, Vim↓, Snail↓, TumW↓, TumCG↓, HK2↓, RB1↓, IL6↓, IL8↓, SOD1↑, RadioS↑, ChemoSen↑, toxicity↓, Sp1/3/4↓, GSH↓, SOD↑,
2949- PL,    Piperlongumine selectively kills glioblastoma multiforme cells via reactive oxygen species accumulation dependent JNK and p38 activation
- in-vitro, GBM, LN229 - in-vitro, GBM, U87MG
selectivity↑, ROS↑, JNK↑, p38↑, GSH↓, eff↓,
2950- PL,    Overview of piperlongumine analogues and their therapeutic potential
- Review, Var, NA
AntiAg↑, neuroP↑, Inflam↓, NO↓, PGE2↓, MMP3↓, MMP13↓, TumCMig↓, TumCI↓, p38↑, JNK↑, NF-kB↑, ROS↑, FOXM1↓, TrxR1↓, GSH↓, Trx↓, cMyc↓, Casp3↑, Bcl-2↓, Mcl-1↓, STAT3↓, AR↓, DNAdam↑,
2951- PL,  AF,    Synergistic Dual Targeting of Thioredoxin and Glutathione Systems Irrespective of p53 in Glioblastoma Stem Cells
- in-vitro, GBM, U87MG
GSH↓, eff↑, GSTP1/GSTπ↓,
2953- PL,    Piperlongumine Acts as an Immunosuppressant by Exerting Prooxidative Effects in Human T Cells Resulting in Diminished TH17 but Enhanced Treg Differentiation
- in-vitro, Nor, NA
*ROS↑, *GSTA1↓, eff↝, *toxicity↓, ROS↑, *Hif1a↓,
2952- PL,    Piperlongumine suppresses bladder cancer invasion via inhibiting epithelial mesenchymal transition and F-actin reorganization
- in-vitro, Bladder, T24/HTB-9 - in-vivo, Bladder, NA
TumCP↓, TumCCA↑, TumCMig↓, TumCI↓, ROS↑, Slug↓, β-catenin/ZEB1↓, Zeb1↓, N-cadherin↓, F-actin↓, GSH↓, EMT↓, CLDN1↓, ZO-1↓,
2965- PL,  docx,    Piperlongumine for enhancing oral bioavailability and cytotoxicity of docetaxel in triple negative breast cancer
- Analysis, Var, NA
BioEnh↑, eff↑,
2963- PL,    Piperlongumine activates Sirtuin1 and improves cognitive function in a murine model of Alzheimer’s disease
- in-vitro, AD, HEK293
*SIRT1↑, *cognitive↑, *Aβ↓, *Inflam↓, *neuroP↑, memory↑, Dose↓, NAD↑,
2962- PL,    Synthesis of Piperlongumine Analogues and Discovery of Nuclear Factor Erythroid 2‑Related Factor 2 (Nrf2) Activators as Potential Neuroprotective Agents
- in-vitro, Nor, PC12
*GSH↑, *NQO1↑, *Trx↑, *TrxR↑, *NRF2↑, *NRF2⇅, *eff↑, *BioAv↑, *ROS↓,
2961- PL,    Piperlongumine inhibits esophageal squamous cell carcinoma in vitro and in vivo by triggering NRF2/ROS/TXNIP/NLRP3-dependent pyroptosis
- in-vitro, ESCC, KYSE-30
Pyro↑, TumCP↓, TumCMig↓, TumCI↓, ASC↑, cl‑Casp1↑, NLRP3↑, GSDMD↑, ROS↑, NRF2↓, TXNIP↑,
2960- PL,    Synthesis of Piperlongumine Analogues and Discovery of Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Activators as Potential Neuroprotective Agents
- Analysis, Nor, NA
NRF2↑, neuroP↑,
2959- PL,    Piperlongumine mitigates LPS-induced inflammation and lung injury via targeting MD2/TLR4
- in-vivo, Nor, NA
*Inflam↓,
2958- PL,    Natural product piperlongumine inhibits proliferation of oral squamous carcinoma cells by inducing ferroptosis and inhibiting intracellular antioxidant capacity
- in-vitro, Oral, HSC3
TumCP↓, lipid-P↑, ROS↑, DNMT1↑, FTH1↓, GPx4↓, eff↓, GSH↓, Ferroptosis↑, MDA↓,
2957- PL,    Piperlongumine Induces Cell Cycle Arrest via Reactive Oxygen Species Accumulation and IKKβ Suppression in Human Breast Cancer Cells
- in-vitro, BC, MCF-7
TumCP↓, TumCMig↓, TumCCA↑, ROS↑, H2O2↑, GSH↓, IKKα↓, NF-kB↓, P21↑, eff↓,
2955- PL,    Heme Oxygenase-1 Determines the Differential Response of Breast Cancer and Normal Cells to Piperlongumine
- in-vitro, BC, MCF-7 - in-vitro, Nor, MCF10
ROS?, *ROS∅, other⇅, HO-1↑, *HO-1↑, NRF2↑, Keap1↓, cl‑PARP↑, selectivity↑, GSH↓, GSSG↑,

Showing Research Papers: 4401 to 4450 of 6108
Prev Page 89 of 123 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 6108

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Catalase↓, 1,   Catalase∅, 1,   Ferroptosis↓, 1,   Ferroptosis↑, 1,   GPx↓, 1,   GPx1∅, 1,   GPx4↓, 1,   GSH?, 1,   GSH↓, 17,   GSSG↑, 3,   GSTP1/GSTπ↓, 2,   GSTs↓, 1,   H2O2↑, 3,   HO-1↑, 3,   Keap1↓, 1,   lipid-P↑, 3,   MDA↓, 1,   MDA↑, 1,   NQO1↑, 1,   NRF2↓, 1,   NRF2↑, 4,   Prx4↓, 1,   Prx4↑, 1,   PrxII↓, 1,   ROS?, 1,   ROS↑, 35,   SOD↑, 1,   SOD∅, 1,   SOD1↑, 2,   SOD2↑, 1,   Trx↓, 2,   Trx1↓, 1,   TrxR↓, 8,   TrxR1?, 1,   TrxR1↓, 2,  

Metal & Cofactor Biology ⓘ

FTH1↓, 1,  

Mitochondria & Bioenergetics ⓘ

mitResp↓, 1,   MMP↓, 2,  

Core Metabolism/Glycolysis ⓘ

cMyc↓, 4,   Glycolysis↓, 2,   HK2↓, 2,   IDO1↓, 1,   LDH↓, 1,   NAD↑, 1,  

Cell Death ⓘ

Akt↓, 4,   p‑Akt↓, 3,   Apoptosis↑, 9,   BAX↓, 1,   BAX↑, 2,   Bcl-2↓, 6,   BIM↑, 1,   cl‑Casp1↓, 1,   cl‑Casp1↑, 1,   Casp3↑, 5,   cl‑Casp3↑, 1,   cl‑Casp3∅, 1,   proCasp3↓, 1,   Casp7↑, 2,   Casp8↑, 1,   Casp9↑, 1,   cl‑Casp9↑, 1,   Cyt‑c↑, 2,   Ferroptosis↓, 1,   Ferroptosis↑, 1,   GSDMD↑, 1,   JNK↑, 3,   MAPK↑, 1,   Mcl-1↓, 1,   MDM2↓, 1,   p38↑, 4,   PUMA↑, 1,   Pyro↑, 1,   survivin↓, 4,   TumCD↑, 1,  

Kinase & Signal Transduction ⓘ

p‑HER2/EBBR2↓, 1,   Sp1/3/4↓, 5,  

Transcription & Epigenetics ⓘ

other⇅, 1,   SETBP1↓, 1,   tumCV↓, 3,  

Protein Folding & ER Stress ⓘ

CHOP↑, 4,   p‑eIF2α↑, 1,   ER Stress↑, 5,   p‑PERK↑, 1,   UPR↑, 1,   XBP-1↑, 1,  

DNA Damage & Repair ⓘ

DNAdam↑, 6,   DNMT1↑, 1,   GADD45A↑, 1,   P53↑, 2,   PARP↑, 1,   cl‑PARP↑, 3,   cl‑PARP∅, 1,   PCNA↓, 2,  

Cell Cycle & Senescence ⓘ

CDK1↓, 1,   CDK2↓, 1,   CDK4↓, 2,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 4,   P21↑, 5,   RB1↓, 1,   p‑RB1↓, 1,   TumCCA↑, 13,  

Proliferation, Differentiation & Cell State ⓘ

cFos↓, 1,   cMET↓, 3,   EMT↓, 3,   ERK↓, 1,   ERK↑, 1,   p‑ERK↓, 1,   FOXM1↓, 1,   p‑FOXO3↓, 1,   GSK‐3β↓, 1,   HDAC↓, 1,   mTOR↓, 4,   Nanog↓, 1,   OCT4↓, 1,   PI3K↓, 1,   PTEN↑, 1,   RAS↓, 1,   SOX2↓, 1,   STAT1↓, 1,   STAT3↓, 4,   STAT6↓, 1,   TOP2↓, 1,   TumCG↓, 4,  

Migration ⓘ

AntiAg↑, 2,   AP-1↓, 1,   Ca+2↑, 1,   CLDN1↓, 1,   E-cadherin↑, 2,   F-actin↓, 1,   FOSB↑, 1,   Ki-67↓, 2,   MMP13↓, 1,   MMP2↓, 2,   MMP3↓, 1,   MMP9↓, 3,   N-cadherin↓, 2,   Slug↓, 3,   SMAD4↑, 1,   Snail↓, 1,   SOX4↑, 1,   TumCI↓, 6,   TumCMig↓, 6,   TumCP↓, 7,   TumMeta↓, 4,   Twist↓, 2,   TXNIP↑, 1,   Vim↓, 1,   Zeb1↓, 2,   ZO-1↓, 1,   β-catenin/ZEB1↓, 2,  

Angiogenesis & Vasculature ⓘ

angioG↓, 2,   ATF4↑, 2,   ATF4↝, 1,   EGFR↓, 2,   HIF2a↓, 1,   NO↓, 1,   NO↑, 1,   VEGF↓, 1,  

Barriers & Transport ⓘ

P-gp↓, 1,  

Immune & Inflammatory Signaling ⓘ

ASC↑, 1,   COX2↓, 1,   CXCR4↓, 1,   ICAM-1↓, 1,   IKKα↓, 2,   IL1β↓, 1,   IL6↓, 3,   IL8↓, 1,   Inflam↓, 4,   JAK1↓, 1,   JAK2↓, 1,   MCP1↓, 1,   NF-kB↓, 3,   NF-kB↑, 1,   PGE2↓, 1,  

Protein Aggregation ⓘ

NLRP3↓, 1,   NLRP3↑, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 1,   CDK6↓, 2,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 3,   BioAv↑, 3,   BioEnh↑, 2,   ChemoSen↑, 5,   Dose↓, 1,   Dose↝, 2,   eff↓, 8,   eff↑, 12,   eff↝, 1,   Half-Life?, 1,   Half-Life↝, 1,   MDR1↓, 1,   MRP1↓, 1,   RadioS↑, 3,   selectivity↑, 16,  

Clinical Biomarkers ⓘ

AR↓, 1,   EGFR↓, 2,   FOXM1↓, 1,   p‑HER2/EBBR2↓, 1,   IL6↓, 3,   Ki-67↓, 2,   LDH↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,   AntiTum↑, 1,   cardioP↑, 1,   K17↓, 1,   memory↑, 1,   neuroP↑, 3,   OS↑, 1,   toxicity↓, 1,   toxicity↑, 1,   toxicity∅, 1,   TumW↓, 2,  
Total Targets: 212

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

GSH↑, 2,   GSSG∅, 1,   GSTA1↓, 1,   HO-1↑, 1,   lipid-P↓, 1,   NQO1↑, 1,   NRF2↑, 1,   NRF2⇅, 1,   Prx4∅, 1,   ROS↓, 1,   ROS↑, 1,   ROS∅, 2,   Trx↑, 1,   TrxR↑, 1,  

Core Metabolism/Glycolysis ⓘ

SIRT1↑, 1,  

Cell Death ⓘ

iNOS↓, 1,  

Transcription & Epigenetics ⓘ

other↝, 1,  

Migration ⓘ

MMP13↓, 1,   MMP3↑, 1,   VCAM-1↓, 1,   α-tubulin↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,   Hif1a↓, 2,   NO↓, 1,   VEGF↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   ICAM-1↓, 1,   IL17↓, 1,   IL1β↓, 1,   IL22↓, 1,   IL6↓, 1,   Inflam↓, 4,   PGE2↓, 1,   TNF-α↓, 1,  

Protein Aggregation ⓘ

Aβ↓, 1,   NLRP3↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,   BioAv↑, 3,   eff↓, 1,   eff↑, 1,   Half-Life↑, 1,  

Clinical Biomarkers ⓘ

IL6↓, 1,  

Functional Outcomes ⓘ

cognitive↑, 1,   hepatoP↑, 1,   neuroP↑, 2,   toxicity↓, 2,  
Total Targets: 46

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page